Manipulating the balance between p53‐dependent and independent mechanisms may have value in cancer treatments where p53 is typically mutated, i.e., if tumor cells can be preferentially shunted to a p53‐independent response they may be more responsive to therapy. Here, TP53 is linked to cancer.